NCT02516462

Brief Summary

Because a large proportion of the embryo's quality is dependent upon the egg, this investigation focuses on treatment of the oocyte during in vitro maturation (IVM). In typical IVF cycles, the egg is recovered when it is mature and ready to be fertilized. However, at this point the oocyte's quality has been set, and cannot be altered. Therefore, to have an impact on oocyte quality the use of in IVM is critical. Development of a successful IVM protocol for clinical use would not only provide an option for women of advanced maternal age, it would also reduce the cost of IVF due to fewer exogenous gonadotropins used for stimulation, and significantly lessen the risk of ovarian hyper-stimulation. The objective of this research study is to evaluate a newly developed oocyte maturation media system for human clinical use in assisted reproductive technology (ART).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2015

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2015

Completed
29 days until next milestone

First Submitted

Initial submission to the registry

July 30, 2015

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 6, 2015

Completed
6.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
Last Updated

May 15, 2020

Status Verified

May 1, 2020

Enrollment Period

6.4 years

First QC Date

July 30, 2015

Last Update Submit

May 13, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pregnancy

    The incidence of pregnancy following embryo transfer of IVM produced embryos.

    6 months after egg retrieval

Secondary Outcomes (5)

  • Development of good quality blastocysts using the Gardner morphological blastocyst grading system

    7 days after egg retrieval

  • Offspring Weight

    1 year after egg retrieval

  • Offspring Gender

    1 year after egg retrieval

  • Fertilization of eggs

    2 days after egg retrieval

  • Euploid Embryos

    1 month after egg retrieval

Study Arms (1)

IVM

EXPERIMENTAL

Immature oocytes recovered from each subject will be placed into IVM media for maturation.

Device: IVM mediaDrug: Follicle Stimulating Hormone (FSH)

Interventions

IVM mediaDEVICE

Media to support the nuclear maturation and cytoplasmic competence of human oocytes in culture.

IVM

Low dose FSH is administered to stimulate follicle growth.

IVM

Eligibility Criteria

Age21 Years - 35 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Infertile women who desire to conceive and come to CCRM for infertility treatment using IVF will be candidates for this study.
  • Women with PCOS
  • Patients can be of any race, culture, sexual orientation or ethnicity.

You may not qualify if:

  • Minors are excluded from participation in this study.
  • Women with a BMI greater than 40
  • Women whose health is such that becoming pregnant carries risk significantly greater than healthy women are excluded from this study, unless they use a gestational carrier under the direction of their physician.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Fertility Laboratories of Colorado

Lone Tree, Colorado, 80124, United States

RECRUITING

National Foundation for Fertility Research

Lone Tree, Colorado, 80124, United States

RECRUITING

MeSH Terms

Conditions

InfertilityHelping Behavior

Interventions

Follicle Stimulating Hormone

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital DiseasesSocial BehaviorBehavior

Intervention Hierarchy (Ancestors)

Gonadotropins, PituitaryGonadotropinsPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPituitary Hormones, AnteriorPituitary HormonesPeptidesAmino Acids, Peptides, and Proteins

Study Officials

  • Rebecca L Krisher, PhD

    CCRM

    STUDY DIRECTOR

Central Study Contacts

Rachel Makloski, RN

CONTACT

Rebecca L Krisher, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 30, 2015

First Posted

August 6, 2015

Study Start

July 1, 2015

Primary Completion

December 1, 2021

Study Completion

December 1, 2022

Last Updated

May 15, 2020

Record last verified: 2020-05

Locations